PMID- 29205308
OWN - NLM
STAT- MEDLINE
DCOM- 20171213
LR  - 20181113
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 123 Suppl 24
DP  - 2017 Dec 15
TI  - Rectal cancer survival in the United States by race and stage, 2001 to 2009:
      Findings from the CONCORD-2 study.
PG  - 5037-5058
LID - 10.1002/cncr.30882 [doi]
AB  - BACKGROUND: In the first CONCORD study, 5-year survival for patients with
      diagnosed with rectal cancer between 1990 and 1994 was <60%, with large racial
      disparities noted in the majority of participating states. We have updated these 
      findings to 2009 by examining population-based survival by stage of disease at
      the time of diagnosis, race, and calendar period. METHODS: Data from the
      CONCORD-2 study were used to compare survival among individuals aged 15 to 99
      years who were diagnosed in 37 states encompassing up to 80% of the US
      population. We estimated net survival up to 5 years after diagnosis correcting
      for background mortality with state-specific and race-specific life table.
      Survival estimates were age-standardized with the International Cancer Survival
      Standard weights. We present survival estimates by race (all, black, and white)
      for 2001 through 2003 and 2004 through 2009 to account for changes in collecting 
      the data for Surveillance, Epidemiology, and End Results Summary Stage 2000.
      RESULTS: There was a small increase in 1-year, 3-year, and 5-year net survival
      between 2001-2003 (84.6%, 70.7%, and 63.2%, respectively), and 2004-2009 (85.1%, 
      71.5%, and 64.1%, respectively). Black individuals were found to have lower
      1-year, 3-year, and 5-year survival than white individuals in both periods; the
      absolute difference in survival between black and white individuals declined only
      for 5-year survival. Black patients had lower 5-year survival than whites at each
      stage at the time of diagnosis in both time periods. CONCLUSIONS: There was
      little improvement noted in net survival for patients with rectal cancer, with
      persistent disparities noted between black and white individuals. Additional
      investigation is needed to identify and implement effective interventions to
      ensure the consistent and equitable use of high-quality screening, diagnosis, and
      treatment to improve survival for patients with rectal cancer. Cancer
      2017;123:5037-58. Published 2017. This article is a U.S. Government work and is
      in the public domain in the USA.
CI  - Published 2017. This article is a U.S. Government work and is in the public
      domain in the USA.
FAU - Joseph, Djenaba A
AU  - Joseph DA
AD  - Division of Cancer Prevention and Control, Centers for Disease Control and
      Prevention, Atlanta, Georgia.
FAU - Johnson, Chris J
AU  - Johnson CJ
AD  - Cancer Data Registry of Idaho, Idaho Hospital Association, Boise, Idaho.
FAU - White, Arica
AU  - White A
AD  - Division of Cancer Prevention and Control, Centers for Disease Control and
      Prevention, Atlanta, Georgia.
FAU - Wu, Manxia
AU  - Wu M
AD  - Division of Cancer Prevention and Control, Centers for Disease Control and
      Prevention, Atlanta, Georgia.
FAU - Coleman, Michel P
AU  - Coleman MP
AD  - Cancer Survival Group, Non-Communicable Disease Epidemiology Unit, London School 
      of Hygiene and Tropical Medicine, London, United Kingdom.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - AIM
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - African Americans/*statistics & numerical data
MH  - Aged
MH  - Aged, 80 and over
MH  - European Continental Ancestry Group/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Rectal Neoplasms/ethnology/*mortality/pathology
MH  - *Registries
MH  - United States/epidemiology
MH  - Young Adult
PMC - PMC6191027
MID - EMS79224
OTO - NOTNLM
OT  - colorectal cancer
OT  - population-based survival
OT  - rectal cancer
OT  - trends
EDAT- 2017/12/06 06:00
MHDA- 2017/12/14 06:00
CRDT- 2017/12/06 06:00
PHST- 2017/02/22 00:00 [received]
PHST- 2017/05/22 00:00 [revised]
PHST- 2017/06/14 00:00 [accepted]
PHST- 2017/12/06 06:00 [entrez]
PHST- 2017/12/06 06:00 [pubmed]
PHST- 2017/12/14 06:00 [medline]
AID - 10.1002/cncr.30882 [doi]
PST - ppublish
SO  - Cancer. 2017 Dec 15;123 Suppl 24:5037-5058. doi: 10.1002/cncr.30882.